Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.85 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.85 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.85 |
| ▸ | MAPT | P10636 | 10/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.85 |
| ▸ | TSHR | P16473 | 5/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.85 |
| ▸ | MEN1 | O00255 | 5/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.85 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.85 |
| ▸ | MTOR | P42345 | 3/20 | 0.85 |
| ▸ | HPGD | P15428 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.85 |
| ▸ | DRD2 | P14416 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL8508110 | 0.94 | MAPT (0.76) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Levisoprenaline SCHEMBL29620666 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Levisoprenaline SCHEMBL250806 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Isoproterenol SCHEMBL4166 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Isoproterenol SCHEMBL29519146 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Isoproterenol SCHEMBL3253794 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Isoproterenol SCHEMBL29386243 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Isoproterenol SCHEMBL4165 | 0.92 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Isoproterenol SCHEMBL1333049 | 0.91 | MAPT (0.97) | MAPTTDP1KDM4EADRB2ADRB1 | |
| Isoproterenol SCHEMBL3672791 | 0.91 | MAPT (1.00) | MAPTTDP1KDM4EADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354722-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-OPERATIVE COMPLICATIONS OF CARDIOPULMONARY SURGERY | MOR RESEARCH APPLICATIONS LTD. (IL) | 2017-12-14 | — | — | US | disclosed |
| EP-3215183-A2 | COMPOSITIONS AND METHODS FOR TREATING POST-OPERATIVE COMPLICATIONS OF CARDIOPULMONARY SURGERY | Mor Research Applications Ltd. (IL) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016071761-A2 | COMPOSITIONS AND METHODS FOR TREATING POST-OPERATIVE COMPLICATIONS OF CARDIOPULMONARY SURGERY | ABRAMOV DAN | 2016-05-12 | — | — | WO | disclosed |
| EP-2699579-A1 | PYRAZOLO [4, 3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-2699572-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-5418160-A | Obesity | THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-05-23 | — | — | US | disclosed |
| US-4404217-A | DRUGS ACTIVE ON CARDIOVASCULAR SYSTEM | C. M. INDUSTRIES (FR) | 1983-09-13 | — | — | US | disclosed |